Bernardo L. Piereck

bernardo-piereck

Bernardo L. Piereck

Partner

Washington, D.C. | 1900 K Street, NW, Washington, DC 20006-1110
+1 202 261 3405 | +1 202 261 3333

| vCard | PDF

Bernardo L. Piereck represents private equity, private company and public company clients on mergers, acquisitions and divestitures, and general corporate and securities matters. His experience includes cross-border mergers and acquisitions involving both strategic and financial buyers, sellers and financial sponsors in inbound and outbound transactions. As part of his private practice, he also has experience in representing public corporations in Securities and Exchange Commission investigations, as well as non-profit organizations on formation, qualification for tax-exempt status and governance practices. Prior to entering private practice, Mr. Piereck worked as an economist at the Federal Energy Regulatory Commission, Washington, D.C. In that capacity, he led the technical economic analyses of market power abuses and anomalous market behavior in the California wholesale energy markets and participated in settlement negotiations regarding refunds, penalties, and compliance plans.
 
Prior to joining Dechert, Mr. Piereck worked in the Washington, D.C. office of an international law firm where he represented clients in the negotiation and drafting of core and ancillary transaction documentation in relation to the acquisition and divestiture of several public and private target companies.

Significant Representations

  • Affiliates of Bregal Partners in connection with its investment in American Seafoods Group, LLC, the largest harvester of wild-caught fish for human consumption in the United States, as part of a broader deleveraging recapitalization of American Seafoods Group, LLC.
  • GIC, the sovereign wealth fund of Singapore, in its US$350 million investment in Kronos Inc., a company focused on delivering workforce management solutions in the cloud, as part of a broader recapitalization of Kronos.
  • Court Square Capital Partners in a number of its transactions, including the US$1.12 billion sale of the Harvard Drug Group to Cardinal Health Inc., and various portfolio company acquisitions.
  • Compañía Perforadora de México S.A.P.I. de C.V. (PEMSA), a wholly-owned subsidiary of Grupo México S.A.B. de C.V., in five acquisitions of jackup rigs and drilling platforms for a total value of approximately US$1 billion for use in oil exploration and drilling in the Gulf of Mexico.
  • Celgene Corporation on its 2015 acquisition of Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery for US$100 million at closing and an additional earnout of US$385 million.
  • Switzerland-based Ferring Pharmaceuticals on its 2014 acquisition of DDAVP® (desmopressin acetate) from Sanofi.
  • R-Pharm US in its acquisition of the breast cancer drug Ixempra (ixabepilone) from Bristol-Myers Squibb.
  • Tekla Capital Management LLC and its affiliates in a broad range of investments in private biotechnology companies.
  • Sweden-based Orexo AB in its sale of the rights to the pharmaceutical product Abstral in the United States to Galena Biopharma, Inc.
  • Guggenheim Investments in its acquisition of Accretive Asset Management LLC, a leading provider of fixed-income indexing solutions and the creator of BulletShares Indices.
  • CorpBanca, a Chilean bank, and its majority shareholders, in connection with a US$225 million investment from the International Finance Corporation (IFC) and certain of its affiliated funds.
Education
  • Florida International University, B.A., 2001, cum laude, Golden Key International Honor Society, Omicron Delta Epsilon International Economics Honor Society, Dean’s List
  • George Mason University School of Law, J.D., 2008, magna cum laude, Managing Editor of The Docket Newspaper, Member of the George Mason Law Review, Trial Advocacy Association, Hispanic Law Students Association
Admissions
  • District of Columbia
  • Virginia
Languages
  • English
  • Portuguese